摘要
目的:评价药物洗脱支架在冠心病合并2型糖尿病患者中的临床疗效。方法:68例冠心病合并2型糖尿病患者接受冠脉内原发病变药物洗脱支架置入(SES组);对照组(BS组)是从我科资料库中抽取的原发病变置入普通支架的56例冠心病合并2型糖尿病患者。结果:术后1年内随访结果SES组与BS组手术成功率相似(分别为97.1%与98.2%,P=1.00)。SES组与BS组累计1年内主要不良心脏事件发生率分别为19.1%与35.7%(P=0.037,OR=0.425,95%CI:0.188~0.961),再次血运重建率为10.3%与25.0%(P=0.03,OR=0.344,95%CI:0.128~0.925),死亡、急性心肌梗死无差异。结论:药物洗脱支架较普通支架显著降低糖尿病患者冠脉介入治疗的1年主要不良心脏事件。
Objective:To evaluate the clinical outcomes of patients with coronary artery disease and type 2 diabetes who underwent elective percutaneous coronary intervention. Methods: From December 2002, a policy of routine sirolimus-eluting stents(SES) implantation has been instituted in our hospital. During 2 years of enrollment, a total of 68 consecutive diabetic patients with coronary lesions were electively treated with SES (SES group). A similar group for comparison comprised 56 consecutive patients treated with bare metal stents in the preceding period (BS group). Results: After 1-year follow-up, the cumulative rate of major adverse cardiac events (death, myocardial in farction, and any repeat revascularization) was 19. 1% in the SES group versus 35.7% in the BS group (P=0. 037,OR=0. 425 ,95%CI: 0. 188-0. 961), mainly due to a marked reduction in the need for repeat revascularization(10.3% versus 25.0%, P = 0. 03 , OR = 0. 344,95% CI 0. 128 0. 925). Conclusions: Routine utilization of SES for diabetic patients significantly reduces the rate of adverse cardiac events at 1 year compared to bare metal .
出处
《国际心血管病杂志》
2006年第3期191-193,共3页
International Journal of Cardiovascular Disease
关键词
药物洗脱支架
冠心病
2型糖尿病
Sirolimus-eluting stents
Coronary artery disease
Type 2 diabetes mellitus